H.C. Wainwright analyst Edward White lowered the firm’s price target on G1 Therapeutics to $3 from $9 and keeps a Buy rating on the shares. The company announced disappointing topline results from its randomized, double-blind, placebo-controlled, Phase 3 PRESERVE 2 study evaluating Cosela in patients receiving chemotherapy for locally advanced unresectable or metastatic triple-negative breast cancer, the analyst tells investors in a research note. The firm removed an expected launch in TNBC from its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics Reports Setback in Phase 3 Cancer Trial
- G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
- G1 Therapeutics participates in a conference call with JPMorgan
- G1 Therapeutics announces inducement grants under Nasdaq listing rule
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)